Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen acquired R&D Technology Rights — Net Carrying Value ($M) ($M)
Form 10-Q / 10-K Goodwill and Other Intangible Assets Note (XBRL)
Latest, Q2 2026
105
Period ended Jun 30, 2026
Change on a year earlier
-19.8%
131 in Q2 2025
History
37 quarters
Since Q4 2015
Sources
34
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up acquired r&d technology rights — net carrying value ($m)
Cite this data
StockData. (2026). Amgen Acquired R&D Technology Rights — Net Carrying Value ($M) ($M), quarterly Q4 2015–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/fl_rdtech_net
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.